Class / Patent application number | Description | Number of patent applications / Date published |
514800300 | Nerve tissue or nerve cell growth affecting | 51 |
20110071078 | METHODS FOR TREATING NEUROLOGICAL DEFICITS - The present invention features methods and compositions for treating a patient who has a neurological deficit. The method can be carried out, for example, by contacting (in vivo or in culture) a neural progenitor cell of the patient's central nervous system (CNS) with a polypeptide that binds the epidermal growth factor (EGF) receptor and directing progeny of the proliferating progenitor cells to migrate en masse to a region of the CNS in which they will reside and function in a manner sufficient to reduce the neurological deficit. The method may include a further step in which the progeny of the neural precursor cells are contacted with a compound that stimulates differentiation. | 03-24-2011 |
20110136738 | Alternatively Transcribed Genes Associated with Schizophrenia - Methods of identifying gene targets associated with schizophrenia or the symptoms thereof, as well as to specific nucleic acid molecules that have been discovered to be associated with schizophrenia are provided. Accordingly, the invention also relates to methods of modulating schizophrenia or the symptoms thereof, methods of diagnosing schizophrenia or the symptoms thereof, methods for predicting the susceptibility to schizophrenia or the symptoms thereof, and methods of identifying compounds that modulate schizophrenia or the symptoms thereof via manipulations of the nucleic acid molecules and their products. | 06-09-2011 |
20110201552 | ISOLATED NUCLEIC ACID MOLECULE ENCODING A NEUROTROPHIC GROWTH FACTOR - There is disclosed an isolated nucleic acid molecule encoding a human neurotrophic growth factor designated enovin and having the amino acid sequence illustrated in FIG. | 08-18-2011 |
20120015878 | USE OF ADNF POLYPEPTIDES FOR TREATING ANXIETY AND DEPRESSION - This invention relates to the use of ADNF polypeptides in the treatment of anxiety and/or depression. The present invention also relates to drug discovery assays using the ADNF polypeptide mechanism of action and target interaction, as well as the manufacture of medicaments, methods of application and formulation therefor. Embodiments of the invention provide methods for preventing and/or treating anxiety and depression disorders in a subject by administering a NAP, an 8-amino-acid peptide derived from Activity Dependent Neurotrophic Factor (ADNF III), in an amount sufficient to improve postnatal performance. The ADNF polypeptides include ADNF I and ADNF III (also referred to as ADNP) polypeptides, analogs, subsequences, and D-amino acid versions (either wholly D-amino acid peptides or mixed D- and L-amino acid peptides), and combinations thereof which contain their respective active core sites and provide neuroprotective and anti-anxiety functions. | 01-19-2012 |
20120214737 | METHODS FOR PROTECTING DOPAMINERGIC NEURONS FROM STRESS AND PROMOTING PROLIFERATION AND DIFFERENTIATION OF OLIGODENDROCYTE PROGENITORS BY NRG-2 - The invention features methods of treatment and diagnosis using NRG-2 polypeptides, nucleic acid molecules, and antibodies. The invention also provides novel NRG-2 polypeptides and nucleic acid molecules. | 08-23-2012 |
20120214738 | THERAPEUTIC AGENT AND THERAPEUTIC METHOD FOR PERIODONTAL DISEASES AND PULPAL DISEASES - The objects of the present invention are: to provide a therapeutic agent and a therapeutic method for periodontal diseases and pulpal diseases, a transplant for periodontal tissue regeneration, and a method for regenerating the periodontal tissue. | 08-23-2012 |
20120258916 | OPHTHALMIC PREPARATIONS BASED ON BDNF (BRAIN-DERIVED NEUROTROPHIC FACTOR) AND THEIR USE - Said preparations can be administered topically to the intact eye surface, and are useful in the prevention and treatment of neurodegenerative disorders of the retina, optic nerve, lateral geniculate body and visual cortex, in order to prevent reduction of visual capacity and restore the normal visual function. | 10-11-2012 |
20130065830 | Dopamine Neuron Stimulating Peptide-11 Protection From Complex 1 Mitochondrial Inhibitors - The present invention relates to the use of novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), for treating brain diseases and injuries that result in dopaminergic deficiencies and mitochodrial dysfunction, e.g., reduced complex I enzyme activity. | 03-14-2013 |
20130123174 | NEURITOGENIC PEPTIDES - The present invention relates to peptide compounds that are capable of stimulating neuronal differentiation, neurite outgrowth and survival of neural cells, and enhancing synaptic plasticity, learning and memory, methods of treating diseases and conditions of nervous system by administration of compositions comprising said compounds. The compounds and compositions of the invention include peptide sequences that are derived from the sequence of human erythropoietin or proteins that are homologous of human erythropoietin. | 05-16-2013 |
20130237477 | COMPOSITIONS AND METHODS FOR INCREASING VASCULARIZATION - Disclosed are methods of increasing vascularization in a tissue by administering a neublastin polypeptide to a mammal exhibiting impaired or inadequate blood flow in the tissue. The methods can be used to in the treatment or prevention of a disorder characterized by impaired or inadequate blood flow or to increase vascularization in an organ that has been transplanted into a subject. | 09-12-2013 |
20130267464 | THERAPEUTIC USE OF A GROWTH FACTOR, METRNL - The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects. | 10-10-2013 |
20140031284 | NEUREGULIN VARIANTS AND METHODS OF SCREENING AND USING THEREOF - The present invention provides polypeptide variants of neuregulin-1β (NRG-1β) that have enhanced or decreased binding affinity to ErbB3 and/or ErbB4. The invention also provides methods of screening and producing polypeptide variants of NRG-1β and methods of using polypeptide variants of NRG-1β for treating diseases. | 01-30-2014 |
20140088009 | CHIMERIC NEUREGULINS AND METHOD OF MAKING AND USE THEREOF - Composition containing a chimeric neuregulin polypeptides and method of making such polypeptides are disclosed. The chimeric neuregulin comprises a first moiety of at least 10 amino acids, wherein the first moiety is derived from a first polypeptide; and a second moiety of at least 5 amino acids, wherein the second moiety is derived from a second polypeptide; wherein the first polypeptide is a neuregulin and the chimeric neuregulin exhibits an enhanced binding affinity to integrin, Erb 3, or Erb 4 comparing to that of the first neuregulin. | 03-27-2014 |
20140135265 | NEUREGULIN PEPTIDES AND THEIR USE - The present invention provides certain neuregulin peptides useful in, for example, methods and compositions comprising preventing, treating or delaying various diseases or disorders. | 05-15-2014 |
20140243264 | METHODS OF TREATMENT FOR RETINAL DISEASES - The present invention provides methods of treating a retinal disorder comprising administering an effective amount of a neurotrophic factor to a subject having the retinal disorder. The neurotrophic factors useful in the invention include mesencephalic astrocyte-derived neurotrophic factor (MANF) and conserved dopamine neurotrophic factor (CDNF). The present invention further comprises pharmaceutical compositions and kits containing MANF and CDNF. | 08-28-2014 |
20140274897 | METHOD FOR PREVENTING AND TREATING DIABETES USING NEURTURIN - The present invention relates generally to methods for preventing and/or treating pancreatic disorders, particularly those related to diabetes, by administering a neurturin protein product. | 09-18-2014 |
20140296142 | GENE THERAPY FOR DIABETIC NEUROPATHY USING AN HGF ISOFORM - The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetic neuropathy, wherein the pharmaceutical composition comprises, as active ingredients, different types of isoforms of HGF or a polynucleotide encoding the isoforms. The present invention is the first invention demonstrating that diabetic neuropathy can be prevented and treated using different types of isoforms of HGF. According to the present invention, it is possible to very effectively treat diabetic neuropathy. | 10-02-2014 |
20140315805 | LOCALLY RELEASED GROWTH FACTORS TO MEDIATE MOTOR RECOVERY AFTER STROKE - Methods of improving recovery of a mammal after an ischemic event (e.g., stroke) are provided. In various embodiments the methods involve administering a neural growth factor (e.g., BDNF) into the infarct (e.g., stroke) cavity in a biocompatible hydrogel formulation. In certain embodiments the hydrogel comprises a thiolated hyaluronan and a thiolated gelatin with an optional thiolated heparin. | 10-23-2014 |
20140349930 | TREATMENT USING NEUBLASTIN POLYPEPTIDES - The invention relates to treatments of neuropathic pain, including tactile allodynia, and to treatments for reducing loss of pain sensitivity associated with neuropathy. The present treatments involve the use of neublastin (NBN) polypeptides. | 11-27-2014 |
20150025008 | Compositions and Methods of Detecting and Treating Neural Tube Defects - The present invention generally relates to compositions, reagents and methods for detecting and treating a neural tube defect in a fetus. One aspect of the invention provides a method including administrating a composition containing noggin or LDN-193189 to the fetus in utero. In certain embodiments, the composition is administrated if the maternal blood or amniotic fluid contains an elevated amount of BMP4 and/or a reduced amount of noggin. In another aspect of the invention, the method includes administrating a composition containing GDC-0449 to the fetus in utero. In certain embodiments, the GDC-0449 is administrated if the maternal blood or amniotic fluid contains an elevated amount of sonic hedgehog. | 01-22-2015 |
20150080302 | NEUREGULIN ISOFORMS, NEUREGULIN POLYPEPTIDES AND USES THEREOF - The present invention relates to new therapeutic and diagnostic uses of soluable neuregulin-1 isoforms and polypeptides, particularly neurological disorders. | 03-19-2015 |
20150094263 | Use of Neuregulin to Treat Peripheral Nerve Injury - The disclosure provides compositions and methods for preventing, ameliorating a sign or symptom of, or treating peripheral nerve injury. | 04-02-2015 |
20160008359 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | 01-14-2016 |
20160008432 | NEUREGULIN BASED METHODS FOR TREATING HEART FAILURE | 01-14-2016 |
20160009774 | NEUREGULIN PEPTIDES AND THEIR USE | 01-14-2016 |
20160022773 | METHODS FOR PROMOTING WOUND HEALING AND HAIR GROWTH - The present invention generally relates to uses of glial cell line-derived growth factor (GDNF) in cutaneous wound healing and hair growth. Methods of effecting hair growth and/or wound healing which feature administration of GDNF, or a biologically active fragment thereof, to subjects, e.g., human subject, are disclosed herein. The invention relates also to formulations and kits for achieving the indicated pharmaceutical advantages. | 01-28-2016 |
20160045487 | COMPOSITIONS AND METHODS FOR TREATING NEUROPATHY - The invention features XIB4035 for the treatment of large fiber neuropathy, and combinations of XIB4035 and GDNF for the treatment of both large and small fiber neuropathies. | 02-18-2016 |
20160095903 | EXTENDED RELEASE OF NEUREGULIN FOR IMPROVED CARDIAC FUNCTION - The present invention provides extended release compositions comprising neuregulin for preventing, treating or delaying various diseases or disorders. The present invention also provides methods for preventing, treating or delaying various diseases or disorders by extended release of neuregulin. | 04-07-2016 |
20160152673 | Dopaminergic Neuronal Survival-Promoting Factors and Uses Thereof | 06-02-2016 |
514800400 | Nerve growth factor (NGF) or derivative | 22 |
20100240582 | Peptides and related molecules that modulate nerve growth factor activity - The present invention relates to certain biologically active peptides and polypeptides which can be used as therapeutics or prophylactics against diseases or disorders linked to NGF as the causative agent. In one aspect of the present invention, pharmacologically active polypeptides comprising peptides linked to one or more Fc domains are provided. | 09-23-2010 |
20100292145 | METHODS OF REGULATING APOPTOSIS - Compounds that modulate the function of anti-apoptotic proteins such as Bcl-2 and related Bcl-2 family members are identified. These compounds have the ability to convert the activity of Bcl-2-family member proteins from anti-apoptotic to pro-apoptotic. Methods for inducing or preventing apoptosis are described, together with methods for identifying molecules that induce or prevent apoptosis through interaction with Bcl-2-family members. Methods for treatment of proliferative diseases and neurodegenerative diseases using the modulators of Bcl-2 and related family members are also disclosed. | 11-18-2010 |
20110021425 | TRICYCLIC INHIBITORS OF JAK - The present invention relates to the use of novel compounds of Formulae I-II, | 01-27-2011 |
20110021426 | METHODS FOR TREATMENT OF PAIN - The invention provides for methods and compositions for treatment of pain via craniofacial mucosal administration of an analgesic compound (e.g. a non-opioid analgesic peptide, an NOP agonist or N/OFQ). Intranasal administration of certain analgesic peptides such as N/OFQ results in global analgesic effects. | 01-27-2011 |
20120010140 | SELF-ASSEMBLING PEPTIDES FOR REGENERATION AND REPAIR OF NEURAL TISSUE - The present invention provides methods and compositions for enhancing regeneration and/or repair of neural tissue. One method include providing a nanoscale structured material at the site of injury, wherein the nanoscale structured material provides an environment that is permissive for regeneration of neural tissue and allows axon growth from a location on one side of a site of injury or barrier to a location on the other side of the site of injury or barrier. A second method includes introducing a composition comprising self-assembling peptides into the subject at the site of injury, wherein the peptides are amphiphilic peptides that comprise substantially equal proportions of hydrophobic and hydrophilic amino acids and are complementary and structurally compatible. A variety of compositions comprising a nanoscale structured material or precursor thereof, and an additional substance such as a regeneration promoting factor, are also provided. In certain embodiments of the invention the nanoscale structured material or precursor thereof comprises self-assembling peptides. The invention further provides compositions and methods for repair of an intervertebral disc, including nucleus pulpusos repair. | 01-12-2012 |
20120122777 | DIAGNOSTIC AGENT FOR ISCHEMIC HEART DISEASE RISK GROUP - The present invention relates to a diagnostic agent for an ischemic heart disease risk group comprising an anti-brain-derived neurotrophic factor antibody as an effective ingredient, to an assay method for an ischemic heart disease risk group performed by measuring a brain-derived neurotrophic factor concentration in blood, and to a suppressive/preventive drug for ischemic heart disease, particularly for post-infarction myocardial remodeling, comprising a brain-derived neurotrophic factor. | 05-17-2012 |
20120129771 | PEPTIDES AND RELATED MOLECULES THAT MODULATE NERVE GROWTH FACTOR ACTIVITY - The present invention relates to certain biologically active peptides and polypeptides which can be used as therapeutics or prophylactics against diseases or disorders linked to NGF as the causative agent. In one aspect of the present invention, pharmacologically active polypeptides comprising peptides linked to one or more Fc domains are provided. | 05-24-2012 |
20120142591 | METHOD OF TREATING INTRAOCCULAR TISSUE PATHOLOGIES WITH NERVE GROWTH FACTOR - Nerve Growth Factor (NGF), in the form of a preparation to be administered over ocular surface, is suggested as being suitable for therapy and/or prophylaxis of intraocular tissue pathologies, with particular reference to sclera, ciliary body, crystalline lens, retina, optic nerve, vitreous body and choroidea affections. When administered in the form of external ophthlamic preparation, for example as collyrium or ointment, NGF is capable to go through ocular tissues and it has been found out that it shows a therapeutic activity not only against retina and optic nerve pathologies but also against affections involving the above reported internal structures of the eye. | 06-07-2012 |
20120252726 | NOVEL NEUROTROPHIC FACTORS - The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same. | 10-04-2012 |
20120316112 | RESCUE OF PHOTORECEPTORS BY INTRAVITREAL ADMINISTRATION OF AN EXPRESSION VECTOR ENCODING A THERAPEUTIC PROTEIN - The invention provides methods for treating ocular diseases using a recombinant vehicle to express a protein useful in the treatment of ocular disease, with particular preference for use of neurotrophin-4 (NT4) for targeting subpopulations of cells in the retina. A genetically engineered gene transfer vector containing sequences encoding a growth factor such as neurotrophin-4 (NT4) is used to transduce cells of the retinal ganglion cell (RGC) layer, in situ, via administration of the vector intravitreally. Accordingly, methods are disclosed for treating subjects in need thereof by therapeutic protein delivery via a recombinant expression vector, including rescue of photoreceptors by targeting the RGC layer subpopulation of retinal cells. | 12-13-2012 |
20130109624 | NOVEL NEUROTROPHIC FACTORS | 05-02-2013 |
20130123175 | Compounds for Delivery of Therapeutic And Imaging Moieties to Nerve Cells - The invention features compounds of the general formula: | 05-16-2013 |
20130130981 | TREATMENT USING NEUBLASTIN POLYPEPTIDES - The invention relates to treatments of neuropathic pain, including tactile allodynia, and to treatments for reducing loss of pain sensitivity associated with neuropathy. The present treatments involve the use of neublastin (NBN) polypeptides. | 05-23-2013 |
20130143809 | NEUROTROPHIC PEPTIDES - The present invention relates to a neurotrophic peptide having an amino acid sequence of VGDGGLFEKKL (SEQ ID NO:1) and alternatively comprising an adamantyl group at the C- and/or N-terminal end. The neurotrophic peptide can rescue cognition, correct impairments in neural cell proliferation and synaptic plasticity, and thus address the cognitive defects associated with Down syndrome. | 06-06-2013 |
20130157946 | NEUROTROPHIC PEPTIDES - The present invention relates to a neurotrophic peptide having an amino acid sequence of VGDGGLFEKKL (SEQ ID NO: 1) and alternatively comprising an adamantyl group at the C- and/or N-terminal end. The neurotrophic peptide can rescue cognition, correct impairments in neural cell proliferation and synaptic plasticity, and thus address the cognitive defects associated with Alzheimer's disease. | 06-20-2013 |
20130178419 | METHOD OF TREATING PAIN BY ADMINISTRATION OF NERVE GROWTH FACTOR - The invention provides methods and compositions for treatment of acute and chronic pain comprising the administration of Nerve Growth Factor. | 07-11-2013 |
20130196908 | METHODS FOR TREATMENT OF PAIN - The invention provides for methods and compositions for treatment of pain via craniofacial mucosal administration of an analgesic compound (e.g. a non-opioid analgesic peptide, an NOP agonist or N/OFQ). Intranasal administration of certain analgesic peptides such as N/OFQ results in global analgesic effects. | 08-01-2013 |
20140018294 | NEUROGENIC BRAIN-DERIVED NEUROTROPHIC FACTOR PEPTIDES - Five tetra peptides corresponding to different active regions of brain derived neurotrophic factor (BDNF) that are neurotrophic and can modulate BDNF signaling in a partial agonist/antagonist way. The peptides offer a therapeutic approach to neural pathologies where BDNF levels are dysregulated. | 01-16-2014 |
20140162951 | ISOLATED NUCLEIC ACID MOLECULE ENCODING A NEUROTROPHIC GROWTH FACTOR - There is disclosed an isolated nucleic acid molecule encoding a human neurotrophic growth factor designated enovin and having the amino acid sequence illustrated in FIG. | 06-12-2014 |
20150119326 | ADMINISTRATION OF ANGIOCIDIN FOR THE TREATMENT OF CANCER - Methods are presented for the therapeutic administration of angiocidin in the treatment of cancers such as glioma, breast cancer, and leukemia. Methods are also presented for inducing growth arrest and/or apoptosis of tumor cells, as well as inducing differentiation of tumor cells to inhibit tumorigenicity and to confer a non-tumor or healthy phenotype. | 04-30-2015 |
20160143993 | TREATMENT OF AUTISM SPECTRUM DISORDERS WITH CILIARY NEUROTROPHIC FACTOR PEPTIDE MIMETIC - A method of treating autism spectrum disorders using a therapeutic amount of a synthetic amino acid sequence corresponding to a portion of human ciliary neurotrophic factor (CNTF). In particular, the synthetic amino acid sequence is VGDGGLFEKKL (SEQ ID NO: 1), referred to as Peptide 6. Peptide 6 was tested and shown to exert a neuroprotective effect by modulating CNTF/JAK/STAT pathway and LIF signaling and enhancing brain derived neurotrophic factor (BDNF) expression. | 05-26-2016 |
20190144858 | COMPOSITIONS AND METHODS FOR MODULATING NEURONAL EXCITABILITY AND MOTOR BEHAVIOR | 05-16-2019 |